Argireline: topical anti-wrinkle cosmetic peptide (acetyl hexapeptide-3)
A synthetic peptide used in face creams and serums that mildly relaxes expression-line muscles to reduce wrinkles like frown lines; a cosmetic ingredient, not an approved drug.
- Class
- Cosmetic peptide (SNAP-25 mimetic; SNARE complex competitive inhibitor)
- Status
- Regulated as a cosmetic ingredient (US FDA cosmetic law; EU CosIng; CIR-assessed). Not approved as a drug for any medical indication. Injection of cosmetic Argireline preparations is not authorized in any jurisdiction in the compiled source.
- Best-supported effect
- Modest reduction in dynamic wrinkle depth (~10–30% from baseline) over 28–60 days of twice-daily topical application at 10% concentration in studied populations; mechanism (competitive SNARE complex inhibition) supported in vitro.
- Main caveat
- Effect size is far below injectable botulinum toxin (50–80% reduction); stratum corneum permeation is the rate-limiting step, not bulk concentration. Most published trials are short (≤2 months) and a meaningful share of the base is manufacturer-associated.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Reference scaffold compound — documented synthesis
Fork this card to add platform evidence →
Reference scaffold — used as positive control in bioassays; activity well established
Fork this card to add platform evidence →
What this is
Argireline is a synthetic cosmetic peptide that works by mildly interfering with the facial-muscle signals that cause expression lines — the kind of wrinkles made by squinting, frowning, and smiling. It is applied in a cream or serum and is one of the most widely used cosmetic peptides globally. The active molecule is a six-amino-acid sequence (Ac-EEMQRR-NH₂) — the raw sequence stored here is EEMQRR, but the commercially active form carries an acetyl group on the N-terminus and an amide on the C-terminus; both modifications are part of the designed structure and explain its stability in formulation.
Argireline is regulated as a cosmetic ingredient in the US, EU, and most major markets — not as a drug. Injecting cosmetic Argireline preparations is not authorized and has caused serious infection in reported cases.
History
Argireline was developed by Lipotec S.A. in Barcelona and trademarked in 2001. The design was biomimetic: Blanes-Mira and colleagues (Int J Biol Macromol, 2002) identified that the N-terminal sequence of SNAP-25 — one of the three SNARE proteins that assemble to drive acetylcholine release at the neuromuscular junction — includes the hexapeptide EEMQRR at residues 12–17, which shows high helical propensity and pronounced coiled-coil probability. Their hypothesis was that an acetylated, amidated version of this fragment could compete with native SNAP-25 in the SNARE complex and partially reduce muscle contraction at expression-line sites, providing a reversible, topical echo of what botulinum toxin achieves by enzymatic cleavage.
The product rode a wave of "needle-free Botox" marketing through the 2000s and 2010s. It is now produced by multiple manufacturers under the INCI names acetyl hexapeptide-3 and acetyl hexapeptide-8 — an INCI nomenclature update, not a sequence change — and appears in hundreds of over-the-counter serums and creams.
What it does
Argireline partially and reversibly reduces the force of facial-muscle contractions, which softens the dynamic expression lines — forehead furrows, crow's feet, glabellar lines — that repeated movements deepen over time. The effect is active only while the peptide is present at the target site; effects diminish after stopping use.
The mechanism is mild compared with botulinum toxin injection. Clinical studies consistently show measurable wrinkle-depth reduction at 10% topical concentration over several weeks, but the magnitude is modest: roughly 17–30% reduction from baseline in studied populations, far below the 50–80% reduction seen with botulinum toxin injection. Stratum corneum permeation is the key practical constraint — only a small fraction of the applied peptide crosses the skin surface to reach the depth of facial musculature, which limits how much SNARE inhibition occurs in practice.
Evidence
- Human: Moderate. Multiple clinical studies, including randomized placebo-controlled trials, report roughly 17–30% wrinkle-depth reduction over 28–60 days of twice-daily topical use at 10% concentration. One open-label study in 10 women using an emulsion containing 10% Argireline twice daily demonstrated measurable wrinkle reduction at the periorbital region (Blanes-Mira and colleagues, 2002). A separate open-label trial using 5% Argireline cream twice daily reported 27% improvement in periorbital lines after 30 days (reported in Wisniewski and colleagues, 2014). A randomized placebo-controlled trial in 60 Chinese adult subjects (3:1 ratio, applied to periorbital wrinkles twice daily for 4 weeks) reported wrinkle-depth improvement. A randomized controlled combination study compared tripeptide-10-citrulline with acetyl hexapeptide-3 against controls; the combination design does not isolate Argireline's independent contribution. A pilot randomized study of topical acetyl hexapeptide-8 as adjunct to botulinum toxin therapy in patients with blepharospasm was published but did not demonstrate statistically significant standalone benefit for blepharospasm endpoints. Most published trials are short (≤2 months) and a meaningful share is manufacturer-associated.
- Animal: Histological studies in aged mouse models found that topical Argireline increased type I collagen fiber content and caused collagen fibers to realign more closely and regularly; type III collagen fibers decreased. These findings supplement the primary SNARE-inhibition story but are separate from the expression-line efficacy data.
- In vitro: SNARE complex inhibition is well-demonstrated in cell-free reconstitution assays using recombinant VAMP, syntaxin, and SNAP-25 (Blanes-Mira and colleagues, 2002). Permeation studies confirm that only a small fraction of applied acetyl hexapeptide-8 crosses the stratum corneum into viable epidermis; an even smaller fraction reaches the depth of facial musculature where neuromuscular junctions sit.
Myths and misconceptions
- "Argireline is topical Botox and produces comparable results." The marketing framing overstates the similarity. Argireline partially and reversibly inhibits SNARE complex assembly; botulinum toxin enzymatically cleaves SNARE proteins outright. In published trials, Argireline at 10% produces roughly 17–30% wrinkle-depth reduction over weeks; botulinum toxin produces 50–80% reduction within days. They are not comparable in magnitude.
- "Higher concentrations produce proportionally better results." Stratum corneum permeation, not vehicle concentration, is the rate-limiting step. Moving from 5% to 10% produces meaningful additional delivery; the published literature does not establish that going above 10% yields proportional clinical benefit, as barrier crossing saturates quickly at relevant concentrations.
- "Cosmetic Argireline can be safely injected for a stronger effect." Cosmetic Argireline preparations are not sterile injectable products. A published case report documented serious facial Mycobacterium abscessus infection following unlicensed injection of a cosmetic Argireline preparation. Injectable cosmetic peptides are not an authorized category.
- "Argireline works instantly." Any immediate tightening sensation on first application is due to film-forming polymers or humectants in the vehicle, not SNARE inhibition. Measurable wrinkle-depth reduction in trials emerges after 14–28 days of consistent use.
- "Argireline paralyzes facial muscles like Botox." Argireline does not paralyze muscles. It modestly and reversibly reduces contraction force via competitive SNARE inhibition. Systemic exposure from topical cosmetic use is negligible; facial expression and eyelid function are not affected.
Known effects
- Dynamic wrinkle-depth reduction — Moderate evidence (multiple clinical trials, 10% topical, 28–60 days)
- Periorbital expression-line improvement — Moderate evidence (human RCTs and open-label studies)
- Collagen fiber remodeling — Preclinical only (aged mouse model histology)
- SNARE complex competitive inhibition — Strong mechanistic evidence (in vitro reconstitution assays)
- Adjunct in blepharospasm — Pilot only; no statistically significant standalone blepharospasm benefit in the published pilot
Safety signals
Argireline is described as very well tolerated in topical cosmetic use across published literature. Mild skin irritation is reported as rare. Contact dermatitis or hypersensitivity is rare and may reflect vehicle excipients (fragrances, preservatives, emulsifiers) as well as the peptide itself.
The most serious documented signal is Mycobacterium abscessus facial infection reported after unlicensed injection of a cosmetic Argireline preparation. This is an injection-specific risk, not a topical-use signal: cosmetic products are not manufactured to injectable sterility standards, and no authorized injectable Argireline product exists.
Long-term topical safety data beyond 2–3 months is not established in formal study. Published sources describe the overall profile based on extensive cosmetic use as favorable, but no dedicated long-term safety trial appears in the available literature. Application to broken, irritated, or actively inflamed skin is described as a context of caution, as compromised barrier increases potential for absorption and irritation. Dedicated safety data in pregnancy, breastfeeding, and pediatric populations is not present.
Regulatory status
- US (FDA): Regulated as a cosmetic ingredient under FDA cosmetic law, not as a drug. Over-the-counter sale in finished cosmetic formulations is permitted without prescription. Not approved for treatment of wrinkles, blepharospasm, or any medical condition. Injection of cosmetic Argireline preparations is not authorized.
- EU: Acetyl hexapeptide-8 is included in the EU Cosmetic Ingredient Database (CosIng) and is broadly permitted in cosmetic formulations.
- Canada / UK / Australia / Japan: Broadly permitted as a cosmetic ingredient across these markets.
- CIR (Cosmetic Ingredient Review): Acetyl hexapeptide-8 has been assessed as safe for cosmetic use at typical formulation levels.
- WADA: Not listed on the WADA Prohibited List. Topical cosmetic use has no systemic performance relevance.
Mechanism
Argireline (Ac-EEMQRR-NH₂) is a six-residue synthetic peptide whose sequence reproduces residues 12–17 of SNAP-25, one of three SNARE proteins — with syntaxin-1 and VAMP-2 — that assemble into the complex that drives synaptic vesicle fusion at the neuromuscular junction (Blanes-Mira and colleagues, 2002).
By competing with native SNAP-25 for incorporation into the SNARE complex, Argireline partially blocks SNARE assembly. The downstream result is reduced acetylcholine release from motor-neuron terminals, decreased force of facial muscle contraction, and softening of the dynamic wrinkles produced by repeated expressions. The inhibition is reversible and dose-dependent — unlike botulinum toxin, which enzymatically cleaves SNARE proteins to produce a long-lasting paralytic effect, Argireline's competitive block is active only while the peptide is present at the junction.
The dominant clinical limitation is delivery. Argireline has a molecular weight of approximately 888 Da and is hydrophilic with multiple charged residues — physicochemical properties that predict poor transdermal penetration. In vitro permeation studies confirm that only a small fraction of applied peptide crosses the stratum corneum into viable epidermis; an even smaller fraction reaches facial musculature depth. This is why in vivo effect sizes are modest relative to the well-characterized in vitro target engagement. Formulation variables — liposomal encapsulation, penetration enhancers, occlusive vehicles — affect delivery, and vehicle composition is a meaningful source of variability across commercial products.
Open questions
- Independent head-to-head comparison with botulinum toxin: Most published comparative framing is implicit (marketing) rather than a rigorous independent head-to-head study against the active comparator. Such a trial has not been published in the available literature.
- Long-term topical efficacy and safety: Daily use over years is common in practice but has not been formally studied. Trials beyond 2–3 months are absent from the available literature.
- Real-world skin-penetration across commercial formulations: "Contains Argireline" does not guarantee equivalent delivery. The effective concentration reaching neuromuscular junctions under everyday use across different vehicle types is poorly characterized.
- Dose-response above 10%: Whether concentrations above 10% yield additional clinical benefit, or only higher surface concentration, is not established.
- Preventative use in younger users: Whether starting Argireline in early adulthood alters long-term expression-line development trajectory has not been studied prospectively.
- Responder vs. non-responder phenotypes: Clinical response is variable; the biological basis (skin thickness, muscle mass, genetic factors) is not characterized.
- Independence of the evidence base: A meaningful share of published work is manufacturer-associated; independent replication depth is a limitation of the current literature.
Related peptides
SNAP-8 is a related cosmetic hexapeptide that extends the same SNARE-inhibition strategy as Argireline, targeting a slightly different region of SNAP-25.
Matrixyl (Palmitoyl Pentapeptide-4) is a widely used cosmetic matrikine peptide that acts on collagen synthesis through a separate signaling pathway — complementary in mechanism rather than overlapping.
GHK-Cu (copper peptide) is another cosmetic tripeptide associated with skin remodeling and wound-healing contexts; it does not share the SNARE-inhibition mechanism.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Should this peptide be tagged with the actual protein it binds, rather than the type of product it is sold in?
If corrected, computer models searching for new drugs would treat this peptide as a SNARE modulator instead of a vague skin ingredient, leading to better predictions and fewer dead ends in peptide drug discovery.
Could removing the acetyl or amide groups turn a mild skin cream ingredient into a much stronger muscle signal blocker?
If true, chemists could design a family of related peptides with graduated strength, from gentle cosmetics to targeted medical treatments for muscle spasm or facial dystonia, simply by changing the end caps.
Could Argireline slip into skin cells and tie up the very proteins it mimics, instead of just sitting on the outside?
If true, cosmetic formulators would focus on getting the peptide inside cells rather than just through the skin surface, which could lead to more reliable anti-wrinkle products and also point toward new uses in conditions where muscle signaling is too active.
Could the same peptide that relaxes facial muscles also reduce redness and irritation by changing how skin cells release inflammatory signals?
If true, the same safe, widely used ingredient could find new life in creams for eczema, rosacea, or skin recovery after laser treatments, helping millions with inflamed skin.
Could changing just the first two building blocks of Argireline make it bind to the wrong muscle proteins and cause unwanted relaxation?
If true, manufacturers could test new versions for these off-target effects before selling them, and doctors would better understand why some patients get stronger or uneven results from different cosmetic peptide brands.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| ranking score | 0.7146822810173035 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | none_monomer |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-23 |
▸citationbibtex
@peptide{pep00014,
sequence = {EEMQRR},
target = {cosmeceutical},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}